W. Bryan Hubbard

Ibogaine is a psychoactive indole alkaloid derived from plants such as Tabernanthe iboga, characterized by hallucinogenic and oneirogenic effects. Ibogaine exhibits complex pharmacology by interacting with multiple neurotransmitter systems, notably affecting opioid, serotonin, sigma, NMDA, and nicotinic acetylcholine receptors; its metabolite noribogaine primarily acts as a serotonin reuptake inhibitor and κ-opioid receptor agonist.

The psychoactivity of the root bark of the iboga tree, T. iboga, one of the plants from which ibogaine is extracted, was first discovered by forager tribes in Central Africa, who passed the knowledge to the Bwiti tribe of Gabon. It was first documented in the 19th century for its spiritual use, later isolated and synthesized for its psychoactive properties, briefly marketed in Europe as a stimulant, and ultimately controversially researched for its potential in treating addiction despite being classified as a controlled substance. Ibogaine can be semisynthetically produced from voacangine, with its total synthesis achieved in 1956 and its structure confirmed by X-ray crystallography in 1960. Its clinical use and development have been limited due to regulatory barriers and serious safety risks, such as toxicity to the heart.

Ibogaine produces a two-phase experience—initially visionary and dream-like with vivid imagery and altered perception, followed by an introspective period marked by lingering side effects, such as nausea and mood disturbances, which may persist for days. Long-term risks include mania and heart issues such as long QT syndrome, and potentially fatal interactions with other drugs.

Only two randomized controlled trials have been conducted on ibogaine and noribogaine for substance use disorders, and while they show preliminary anti-addictive potential, their safety and efficacy are unconfirmed, with significant risks including cardiotoxicity and fatalities. Ibogaine is federally illegal in the United States. It is used in treatment clinics abroad under legal gray areas, with growing media attention. It has inspired the development of non-hallucinogenic, non-cardiotoxic analogues like 18-MC and tabernanthalog for therapeutic use. In 2025, Texas allocated $50 million for clinical research on ibogaine to develop FDA-approved treatments for opioid use disorder, co-occurring substance use disorders, and other ibogaine-responsive conditions. A 2026 US executive order directed federal agencies to accelerate review of ibogaine.